Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Altimmune Q4 GAAP EPS $(0.54) Misses $(0.43) Estimate, Sales $37.00K Up From $(110.00K) YoY

Author: Benzinga Newsdesk | March 27, 2024 07:04am
Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.43) by 25.58 percent. This is a 25.58 percent decrease over losses of $(0.43) per share from the same period last year. The company reported $37.00 thousand in sales this quarter. This is a 133.64 percent increase over sales of $(110.00 thousand) the same period last year.

Posted In: ALT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist